{"filings":[{"id":95967,"accession_number":"0001628280-26-032093","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ginkgo Bioworks Q1 revenue $19M (-49% YoY); narrows net loss; cash burn guidance reaffirmed","event_type":"earnings","confidence":"high","bullets":["Revenue $19M, down 49% YoY; prior year included $7M non-cash deferred revenue release; adjusted EBITDA -$42M.","GAAP net loss from continuing ops -$76M (vs -$83M prior year); operating cash burn trajectory reaffirmed.","Completed Biosecurity divestiture on April 3, 2026; results presented as discontinued ops.","Cash, cash equivalents and marketable securities $373M as of March 31, 2026.","Reaffirms FY 2026 total cash burn guidance of $(150)-$(125) million."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":19474000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95966,"accession_number":"0001628280-26-024101","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"Ginkgo completes sale of Biosecurity segment to Tower Biosecurity, retains 20% stake","event_type":"m_and_a","confidence":"high","bullets":["On April 3, 2026, Ginkgo contributed all Biosecurity equity to Tower Biosecurity (Perimeter Systems) for ~20% of buyer's fully diluted shares.","Biosecurity will be reported as discontinued operations starting Q1 2026; pro forma results show reduced operating losses.","Pro forma 2025 net loss improved to $287.8M from $312.8M; 2024 loss improved to $507.6M from $547.0M.","The retained 20% stake will be equity-method accounted; preliminary valuation of $12.3M.","Ginkgo and Tower entered a Transition Services Agreement for temporary services."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109434,"accession_number":"0001628280-26-012552","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Ginkgo Bioworks sells Biosecurity segment to Tower Biosecurity for 20% stake","event_type":"m_and_a","confidence":"high","bullets":["Ginkgo contributes all equity of Ginkgo Biosecurity, LLC (its Biosecurity segment) to Tower Biosecurity.","In exchange, Ginkgo receives shares representing ~20% of Tower Biosecurity on a fully diluted basis.","Transaction expected to close in first half of 2026, subject to customary closing conditions.","Seller is Ginkgo Bioworks, Inc.; parent Ginkgo Bioworks Holdings is party for limited purposes.","No cash purchase price disclosed; consideration is solely an equity stake in the acquirer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109433,"accession_number":"0001628280-26-012339","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ginkgo Q4 revenue $33M (-24% YoY); announces biosecurity spin-off, FY2026 cash burn guidance $150-125M","event_type":"earnings","confidence":"high","bullets":["Q4 2025 total revenue $33M, down 24% YoY; Cell Engineering $26M (-26%), Biosecurity $7M (-22%).","GAAP net loss $(81)M improved from $(108)M; Adjusted EBITDA $(36)M vs $(57)M.","Full year 2025 revenue $170M (-25%); GAAP net loss $(313)M; Adjusted EBITDA $(167)M; cash $423M.","Announced divestiture of biosecurity business to investor consortium for minority equity stake; expected close H1 2026.","Strategic focus on autonomous labs; decommissioning lab benches; collaborations with OpenAI and PNNL ($47M contract). FY2026 cash burn guidance $(150)-$(125)M."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":170155000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125924,"accession_number":"0001628280-25-058791","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Ginkgo Bioworks COO Reshma Shetty transitions role; Jennifer Wipf assumes ops duties","event_type":"leadership","confidence":"high","bullets":["Dr. Reshma Shetty steps down as COO effective Jan 1, 2026; remains President and Board member.","She will focus on expanding autonomous lab for cell engineering service offerings.","CEO Dr. Jason Kelly assumes principal operating officer oversight duties.","Jennifer Wipf (ex-CCO/GM) takes on day-to-day operations, reporting to Kelly.","Wipf brings vaccine and plant management experience from over a decade at Merck."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125923,"accession_number":"0001830214-25-000013","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ginkgo Q3 revenue $39M (-56% YoY); net loss $81M; reaffirms FY guide $167-187M","event_type":"earnings","confidence":"high","bullets":["Total revenue $39M, down 56% YoY; prior year had $45M non-cash deferred revenue; ex that, down 11%.","GAAP net loss $81M vs $56M prior; Adjusted EBITDA loss $56M vs $20M.","Reaffirms FY25 revenue $167-187M; Cell Engineering $117-137M; Biosecurity at least $40M.","Cash & securities $462M; expands autonomous lab; Bayer partnership extended, BARDA contract up to $22.2M.","Cell Engineering revenue $29M (-61% YoY); Biosecurity $9M ($14M prior)."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":136759000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142676,"accession_number":"0001830214-25-000009","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Ginkgo Bioworks enters $100M at-the-market equity sales agreement with Allen & Company","event_type":"other_material","confidence":"high","bullets":["Up to $100M in Class A common stock may be sold through Agent Allen & Company.","Agent receives commission of up to 3% of gross proceeds from each sale.","Registration statement on Form S-3 declared effective August 14, 2025; prospectus supplement dated Sept 4, 2025.","Net proceeds to be used for general corporate purposes including operations, tech development, working capital.","Company may terminate Sales Agreement with sufficient written notice; no assurance any shares will be issued."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142675,"accession_number":"0001628280-25-041399","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2025-08-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Court grants preliminary approval to Ginkgo Bioworks derivative settlement; $4.125M from insurance","event_type":"litigation","confidence":"high","bullets":["Company receives $4.125M from insurance; plaintiffs' counsel may request $2.75M in fees.","Settlement requires Ginkgo to adopt corporate governance reforms.","Derivative actions (Hu, Bowers, In re Ginkgo) will be dismissed with prejudice.","Final hearing set for December 18, 2025; settlement entered on May 27, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142674,"accession_number":"0001628280-25-038981","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ginkgo Q2 2025 revenue $50M, net loss $60M; achieves $250M cost savings goal ahead of schedule","event_type":"earnings","confidence":"high","bullets":["Total revenue $50M, down from $56M YoY; Cell Engineering rev up 8% to $39M; Biosecurity down to $10M.","GAAP net loss $60M, improved from $217M YoY; Adjusted EBITDA -$28M, up from -$99M.","Achieved $250M annualized cost reduction target three months ahead of schedule.","Cash, equivalents, marketable securities $474M as of June 30, 2025.","Reaffirmed FY2025 total revenue outlook $167-187M; Cell Engineering $117-137M; Biosecurity at least $40M."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":97922000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160738,"accession_number":"0001628280-25-031304","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Ginkgo Bioworks shareholders elect all seven director nominees at 2025 annual meeting","event_type":"other","confidence":"high","bullets":["All seven director nominees elected, including Jason Kelly and Reshma Shetty (Class B) and five others.","Ratification of Deloitte & Touche as independent auditor for FY2025 approved with 118.2M votes for.","Advisory vote on executive compensation passed with 107.2M votes for (approx. 99.2% of votes cast).","Three proposals passed; no broker non-votes on ratification and advisory votes were disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160737,"accession_number":"0001628280-25-027058","cik":1830214,"company_name":"Ginkgo Bioworks Holdings, Inc.","ticker":"DNA","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Ginkgo CFO Dmytruk to resign May 30; CAO Coen appointed CFO","event_type":"leadership","confidence":"high","bullets":["Mark Dmytruk resigns as CFO, effective May 30, 2025, to accept a position at another organization.","Steven Coen, CAO, becomes CFO, principal financial officer, and principal accounting officer.","Coen has 30+ years of experience, previously EVP & Corporate Controller at Charles River Labs, and audit at Deloitte.","Coen's base salary is $460,000; he receives a PSU award of 67,991 shares tied to 2025 cash flow objectives.","Coen joined Ginkgo in May 2023 and is a CPA in Massachusetts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}